CN1352649A - 来自tt病毒序列的肽和结合tt病毒的单特异性抗体 - Google Patents
来自tt病毒序列的肽和结合tt病毒的单特异性抗体 Download PDFInfo
- Publication number
- CN1352649A CN1352649A CN00807153A CN00807153A CN1352649A CN 1352649 A CN1352649 A CN 1352649A CN 00807153 A CN00807153 A CN 00807153A CN 00807153 A CN00807153 A CN 00807153A CN 1352649 A CN1352649 A CN 1352649A
- Authority
- CN
- China
- Prior art keywords
- peptide
- thr
- seq
- pro
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 87
- 241000960387 Torque teno virus Species 0.000 title claims abstract description 47
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 8
- 239000007790 solid phase Substances 0.000 claims abstract description 3
- 150000001413 amino acids Chemical group 0.000 claims description 16
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- ZXKNLCPUNZPFGY-LEWSCRJBSA-N Ala-Tyr-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N ZXKNLCPUNZPFGY-LEWSCRJBSA-N 0.000 claims description 4
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 claims description 4
- 108010079364 N-glycylalanine Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims description 4
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 claims description 3
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 claims description 3
- 108010029539 arginyl-prolyl-proline Proteins 0.000 claims description 3
- 108010026333 seryl-proline Proteins 0.000 claims description 3
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 claims description 2
- OTUQSEPIIVBYEM-IHRRRGAJSA-N Arg-Asn-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OTUQSEPIIVBYEM-IHRRRGAJSA-N 0.000 claims description 2
- WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 claims description 2
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 claims description 2
- KHBLRHKVXICFMY-GUBZILKMSA-N Asp-Glu-Lys Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O KHBLRHKVXICFMY-GUBZILKMSA-N 0.000 claims description 2
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 claims description 2
- HJZLUGQGJWXJCJ-CIUDSAMLSA-N Asp-Pro-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJZLUGQGJWXJCJ-CIUDSAMLSA-N 0.000 claims description 2
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 claims description 2
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 claims description 2
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 claims description 2
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 claims description 2
- FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 claims description 2
- NULSANWBUWLTKN-NAKRPEOUSA-N Ile-Arg-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N NULSANWBUWLTKN-NAKRPEOUSA-N 0.000 claims description 2
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 claims description 2
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 claims description 2
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 claims description 2
- ORWTWZXGDBYVCP-BJDJZHNGSA-N Leu-Ile-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(C)C ORWTWZXGDBYVCP-BJDJZHNGSA-N 0.000 claims description 2
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 claims description 2
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 claims description 2
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 claims description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 claims description 2
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 claims description 2
- LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 claims description 2
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 claims description 2
- PELXPRPDQRFBGQ-KKUMJFAQSA-N Lys-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O PELXPRPDQRFBGQ-KKUMJFAQSA-N 0.000 claims description 2
- DCHHUGLTVLJYKA-FXQIFTODSA-N Met-Asn-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DCHHUGLTVLJYKA-FXQIFTODSA-N 0.000 claims description 2
- XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 claims description 2
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 claims description 2
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 claims description 2
- RNMRYWZYFHHOEV-CIUDSAMLSA-N Ser-Gln-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RNMRYWZYFHHOEV-CIUDSAMLSA-N 0.000 claims description 2
- FKZSXTKZLPPHQU-GQGQLFGLSA-N Ser-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CO)N FKZSXTKZLPPHQU-GQGQLFGLSA-N 0.000 claims description 2
- GKMYGVQDGVYCPC-IUKAMOBKSA-N Thr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)N GKMYGVQDGVYCPC-IUKAMOBKSA-N 0.000 claims description 2
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 claims description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 claims description 2
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 claims description 2
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 claims description 2
- 108010013835 arginine glutamate Proteins 0.000 claims description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 claims description 2
- 108010077245 asparaginyl-proline Proteins 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 108010077112 prolyl-proline Proteins 0.000 claims description 2
- 108010080629 tryptophan-leucine Proteins 0.000 claims description 2
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 claims 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 claims 1
- SUMJNGAMIQSNGX-TUAOUCFPSA-N Arg-Val-Pro Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(O)=O SUMJNGAMIQSNGX-TUAOUCFPSA-N 0.000 claims 1
- FMVLWTYYODVFRG-BQBZGAKWSA-N Gly-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN FMVLWTYYODVFRG-BQBZGAKWSA-N 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- BFYHIHGIHGROAT-HTUGSXCWSA-N Phe-Glu-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFYHIHGIHGROAT-HTUGSXCWSA-N 0.000 claims 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 claims 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 claims 1
- JXKMXEBNZCKSDY-JIOCBJNQSA-N Thr-Asp-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O JXKMXEBNZCKSDY-JIOCBJNQSA-N 0.000 claims 1
- KRGDDWVBBDLPSJ-CUJWVEQBSA-N Thr-His-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O KRGDDWVBBDLPSJ-CUJWVEQBSA-N 0.000 claims 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 claims 1
- 108010060035 arginylproline Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 4
- -1 dinitrobenzene diamines Chemical class 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- AAWLEICNDUHIJM-MBLNEYKQSA-N Ala-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C)N)O AAWLEICNDUHIJM-MBLNEYKQSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical group CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 1
- QUGRFWPMPVIAPW-IHRRRGAJSA-N Ser-Pro-Phe Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QUGRFWPMPVIAPW-IHRRRGAJSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- LRHBBGDMBLFYGL-FHWLQOOXSA-N Tyr-Phe-Glu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LRHBBGDMBLFYGL-FHWLQOOXSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Exhaust Gas After Treatment (AREA)
Abstract
描述了具有氨基酸序列SEQ ID No:1的肽,和可选地与一个或多个序列为SEQ ID No:13－11的肽混合的该肽。所有这些肽对应于TT病毒基因组序列区域。还公开了结合TT病毒的单特异性抗体。这些肽可偶联到载体和/或标记上,或固定到固相上。该肽或肽混合物,或单特异性抗体可用于药物或诊断试剂盒中。该肽或肽混合物还可用于免疫非人哺乳动物,以生产抗TT病毒的单特异性抗体。
Description
本发明涉及来自TT病毒基因组序列的肽和结合TT病毒的单特异性抗体。本发明还涉及本发明的肽或抗体分别用于药物。含有本发明的肽作为诊断抗原的诊断试剂盒和含有本发明的抗体作为诊断抗原的诊断试剂盒也包括在本发明之中。本发明的肽可用来免疫非人哺乳动物，以产生针对TT病毒的单特异性抗体。背景
1997年从患有输血后非甲-庚型肝炎的日本患者血清中发现了一种新的人传染源，命名为TT病毒(TTV)[1]。在47％暴发型非甲-庚型肝炎患者和46％未知病因的慢性肝病患者中检出了TTV DNA[2]，表明TTV可能为一些自发性肝病的病因。TTV在全球范围内存在[3]，似乎在感染血液传播病毒的高危人群中更为普遍[2]，如血友病病人和吸毒者中。然而，肠胃传播似乎也是可能的[2]。
TTV为无包膜单链DNA病毒，基因组至少为3.7kb[4]。它具有广泛的序列变异，可分为不同基因型和亚型[4]。在文献[4]中已讨论了它与细小病毒科的关系。随后分析表明了TTV的嗜肝性[2]，在一些非甲-庚型输血后肝炎和TTV DNA病毒血症患者中，TTV DNA滴度与氨基转移酶水平相关[1]。
然而，不能进一步证实TTV感染和严重肝病的联系[3，5，6]。TTV感染的流行病学、免疫学和临床重要性仍不明确。而且，至今仍没有TTV感染的血清学检测，目前PCR是唯一的诊断工具。
能够诊断TTV对人的感染并开发基于免疫肽和/或抗TTV抗体的药物是人们所希望的。
发明描述
本发明基于对应于最近描述的TT病毒(TTV；[1])基因组序列不同区域的合成肽。合成了对应于两个开放读码框(ORFs；Genebank登记号AB008394)1和2的总共80个重叠肽。用8份TTV感染的人血清样品和8份无TTV感染的人样品对它们进行分析。可反应性人血清样品均与具有序列SEQ ID NO：1：TATTTTYAYPGTNRPPV的肽反应。反应性可精确地作图到序列SEQ ID NO：2：YAYPGTNRPPV，发现其中PV残基为结合人抗体最必需的。
这样，本发明针对具有氨基酸序列SEQ ID NO：1TATTTTYAYPGTNRPPV的多肽，其中N-末端氨基酸TATTTT中的一到所有六个可以去除。
在本发明的一个实施方案中，本发明的肽具有氨基酸序列SEQ ID NO：2
YAYPGTNRPPV。
本发明也针对包含肽SEQ ID NO：1(TATTTTYAYPGTNRPPV，其中N-末端氨基酸TATTTT中的一到所有六个可以去除)和至少一个在表4中列出的具有氨基酸序列SEQ ID NO：3-11的其它肽的肽混合物。
本发明的肽和/或肽混合物中至少一个肽可以偶联到载体和/或标记上。载体的实例为塑料表面，如微量滴定板和珠子等；有机分子如生物素；蛋白如牛血清白蛋白；肽接头或多肽。可使用的标记实例(主要用于诊断目的)为放射性同位素、酶和荧光标记等。
此外，本发明的肽和/或肽混合物中至少一个肽可以被固定到固相上，如玻璃或塑料表面，主要用于诊断目的或纯化抗体。
本发明也涉及将本发明的肽或肽混合物可选地与其它生物活性或非活性成分偶联或组合，用作药物，如预防TT病毒感染的疫苗。
此外，本发明针对结合TT病毒的单特异性抗体。
在本发明的一个实施方案中，单特异性抗体结合选自氨基酸序列SEQID NO：1-11的氨基酸序列。
此外，本发明涉及根据本发明的单特异性抗体可选地与其它生物活性或非活性成分偶联或组合，用作药物，如给已经感染了TTV的患者施用的药物。
本发明还针对含有根据本发明的肽或肽混合物作为诊断抗原的诊断试剂盒。该试剂盒可用于免疫学分析如EIA、RIA等，来检测生物学体液(如血液或血浆)中抗TTV抗体的存在。
本发明还针对含有根据本发明的一个或多个单特异性抗体作为诊断抗体的诊断试剂盒。该试剂盒可用于免疫学分析如EIA、RIA等，来检测生物学体液(如血液或血浆)中抗TTV抗体的存在。
该诊断试剂盒通常包含进行免疫学分析的其它成分。这些其它成分将取决于使用的实际分析方法，通常包括阳性和阴性标准血清样品和使用说明书。
此外，本发明针对根据本发明的肽在免疫非人哺乳动物以产生针对TT病毒的单特异性抗体中的用途。
通过参考以下实验描述和本发明的具体实施方案，本发明将被进一步阐明。这些实验描述和具体实施方案不认为是对权利要求书中定义的本
发明范围的限制。实验描述
血清样品
从含有健康血液供体、有或无肝病的儿童、静脉使用毒品(IVDU)的母亲和她们的小孩的血清库获得编号血清样品。
PCR扩增检测血清中的TTV DNA
从50μl患者血清中通过酚/氯仿纯化分离总DNA。所有患者DNA使用两套不同引物通过(半)巢式PCR进行分析。5μl患者DNA加入45μl含有1U taq聚合酶(Perkin-Elmer Applied Biosystems，Norwalk，CO)，10×PCR缓冲液，200μmol MgCl2，dNTPs(125μmol/核苷酸)和20pmol每种引物的反应混合物中。第一轮引物为5TTVout5(5’-ACA GAC AGA GGA GAAGGC AAC ATG-3’)和或者3TTVout(5’-CTG GCA TTT TAC CAT TTC CAA AGT T-3’)或者3TTXout(5’-TAC CAY TTA GCT CTC ATT CTW AT-3’)作为下游引物。DNA扩增如下：95℃4.5分钟；然后95℃30秒，50℃30秒，72℃1分钟，共33循环；最后72℃4分钟。使用5μl第一轮PCR产物在相同条件下进行第二轮PCR。第二轮内引物为5TTVin(5’GGC AAC ATG YTR TGG ATA GACTGG-3’)或5TTVXin(5’-ACA GGA GAC HMA AAC ATA SA-3’)作为上游引物和3TTVout。通过琼脂糖凝胶电泳(3％)确定大约分别为275bp和140bp的正确大小。两套引物均为阳性或一套引物可重复出现阳性的样品判定为TTV阳性。引物序列根据Genebank录入号AB008394。
肽合成
通过多肽合成仪使用标准Fmoc化学方法[7](Syro，Synter，德国)制备对应于TTV的ORF1和ORF2(表1；Genebank录入号AB008394)的重叠肽(18个氨基酸长，8个氨基酸重叠)。
检测血清中的人抗体
EIAs主要按照以前的操作流程[8]。用含有10μg/ml合成肽的0.05M碳酸钠缓冲液(pH9.6)包被微量滴定板(Nunc，丹麦)48小时。用含有1％牛血清白蛋白、2％山羊血清和0.05％Tween 20(稀释缓冲液)的磷酸缓冲盐水室温封闭2小时后，用稀释缓冲液1∶100稀释的人血清孵育微量滴定板。用结合碱性磷酸酶的抗人IgG抗体(Sigma Chemicals，St.Louis，MO)来指示结合的人IgG，通过加入二硝基苯二胺(Sigma)显色，测定405nm处的光密度。
免疫和诱生TTV特异性抗体
用在完全弗氏佐剂中1∶1乳化的100μg肽35(SEQ ID NO：1)通过腹膜内免疫多组Balb/c。四周后用不完全弗氏佐剂中的100μg剂量进行加强。每星期采集静脉血样品，共6星期，并检测对TTV肽35(SEQ ID NO：1)的反应性。
结果
表2和3给出了对覆盖ORF1和ORF2的97个肽的人反应性。发现ORF1中的反应性肽是肽10(SEQ ID NO：3)、18(SEQ ID NO：4)、29(SEQ ID NO：5)、35(SEQ ID NO：1)、42(SEQ ID NO：6)、44(SEQ ID NO：7)、50(SEQ IDNO：8)、51(SEQ ID NO：9)和69(SEQ ID NO：10)(表2)。两份被检测的人血清与来源于ORF2的肽19(SEQ ID NO：11)有反应。所有反应性肽列于表4。最常检测到的肽为具有序列TATTTTYAYPGTNRPPV(SEQ ID NO：1)的肽35。对肽35的反应性依赖于血清样品的稀释度(表5)。微量滴定板上人血清对该肽的反应性可被溶液中相同肽的加入所抑制，但不被非相关肽所抑制(未显示数据)。这表明该反应性对具有序列TATTTTYAYPGTNRPPV(SEQ ID NO：1)的肽35是特异的。
通过使用缺失和替换肽类似物进一步表征肽TATTTTYAYPGTNRPPV的反应性。分析表明识别区域含有序列YAYPGTNRPPV(SEQ ID NO：2)(表6)。使用丙氨酸替换类似物发现Pro-Val序列为人抗体结合最为必需的序列(表6)。
表1.用于合成80个重叠肽的TTV ORFs1和2的完整氨基酸序列(Genebank录入号AB008394)。ORF1MAYGWWRRRRRRWRRWRRRPWRRRWRTRRRRPARRRGRRRNVRRRRRGGRWRRRYRRWKRKGRRRKKAKIIIRQWQPNYRRRCNIVGYIPVLICGENTVSRNYATHSDDTNYPGPFGGGMTTDKFTLRILYDEYKRFMNYWTASNEDLDLCRYLGVNLYFFRHPDVDFIIKINTMPPFLDTELTAPSIHPGMLALDKRARWIPSLKSRPGKKHYIKIRVGAPRMFTDKWYPQTDLCDMVLLTVYATAADMQYPFGSPLTDSVVVNFQVLQSMYDKTISLLPDEKSQREILLNKIASYIPFYNTTQTLAQLKPFIDAGNVTSGATATTWASYINTTKFTTATTTTYAYPGTNRPPVTMLTCNDSWYRGTVYNTQIQQLPIKAAKLYLEATKTLLGNTFTNEDYTLEYHGGLYSSIWLSPGRSYFETTGAYTDIKYNPFTDRGEGNMLWIDWLSKKNMNYDKVQSKCLISDLPLWAAAYGYVEFCAKSTGDQNIHMNARLLIRSPFTDPQLLVHTDPTKGFVPYSLNFGNGKMPGGSSNVPIRMRAKWYPTLFHQQEVLEALAQSGPFAYHSDIKKVSLGMKYRFKWTWGGNPVRQQVVRNPCKETHSSGNRVPRSLQIVDPKYNSPELTFHTWDFRRGLFGPKAIQRMQQQPTTTDIFSAGRKRPRRDTEVYHSSQEGEQKESLLFPPVKLLRRVPPWEDSQQEESGSQSSEEETQTVSQQLKQQLQQQRILGVKLRLLFNQVQKIQQNQDINPTLLPRGGDLASLFQIAPORF2MAEFSTPVRSGEATEGDLRVPRAGAEGEFTHRSQGAIRARDWPGYGQGSEKSMFIGRHYRKKRALSLCAVRTTKKACKLLIVMWTPPRNDQHYLNWQWYSSILSSHAAMCGCPDAVAHFNHLASVLRAPQNPPPPGPQRNLPLRRLPALPAAPEAPGDRAPWPMAGGAEGEDGGAGGDADHGGAAGGPEDADLLDAVAAAE
表2.在EIA中分析对与TT病毒完整开放读码框1(ORF1)对应的重叠合成肽的人抗体反应性。给出数值为405nm处的光密度。OD值大于0.500判定为阳性，并用粗体标出。
| TTVORF1肽 | 通过PCR确定为TTVDNA阴性的样品 | 通过PCR确定为TTV DNA阳性的样品 | ||||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 11 | 9 | 18 | 36 | 48 | 98 | 110 | 155 | 157 | |
| 1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2 | 0.08 | 0.08 | 0.07 | 0.11 | 0.07 | 0.09 | 0.08 | 0.14 | 0.07 | 0.06 | 0.08 | 0.10 | 0.05 | 0.08 | 0.07 | 0.08 |
| 3 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 4 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 6 | 0.08 | 0.08 | 0.07 | 0.10 | 0.07 | 0.09 | 0.07 | 0.11 | 0.08 | 0.06 | 0.08 | 0.09 | 0.05 | 0.07 | 0.08 | 0.07 |
| 7 | 0.07 | 0.07 | 0.08 | 0.10 | 0.07 | 0.08 | 0.08 | 0.10 | 0.07 | 0.064 | 0.07 | 0.09 | 0.05 | 0.07 | 0.08 | 0.08 |
| 8 | 0.07 | 0.06 | 0.07 | 0.08 | 0.07 | 0.09 | 0.07 | 0.10 | 0.07 | 0.07 | 0.08 | 0.10 | 0.05 | 0.07 | 0.09 | 0.09 |
| 9 | 0.07 | 0.08 | 0.08 | 0.09 | 0.08 | 0.10 | 0.07 | 0.10 | 0.08 | 0.06 | 0.07 | 0.10 | 0.05 | 0.08 | 0.10 | 0.11 |
| 10 | 0.09 | 0.10 | 0.11 | 0.11 | 0.11 | 0.13 | 1.09 | 0.12 | 0.09 | 0.07 | 0.07 | 0.11 | 0.06 | 0.09 | 0.12 | 0.12 |
| 11 | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.11 | 0.09 | 0.12 | 0.09 | 0.07 | 0.08 | 0.10 | 0.07 | 0.08 | 0.12 | 0.13 |
| 12 | 0.09 | 0.09 | 0.10 | 0.10 | 0.08 | 0.11 | 0.09 | 0.12 | 0.10 | 0.08 | 0.08 | 0.11 | 0.06 | 0.08 | 0.13 | 0.13 |
| 13 | 0.09 | 0.08 | 0.08 | 0.09 | 0.08 | 0.09 | 0.09 | 0.10 | 0.09 | 0.07 | 0.08 | 0.10 | 0.07 | 0.08 | 0.11 | 0.11 |
| 14 | 0.09 | 0.10 | 0.11 | 0.11 | 0.08 | 0.12 | 0.09 | 0.12 | 0.08 | 0.07 | 0.07 | 0.09 | 0.05 | 0.07 | 0.14 | 0.14 |
| 15 | 0.08 | 0.09 | 0.11 | 0.10 | 0.09 | 0.13 | 0.09 | 0.13 | 0.09 | 0.06 | 0.07 | 0.13 | 0.05 | 0.08 | 0.15 | 0.16 |
| 16 | 0.08 | 0.09 | 0.08 | 0.10 | 0.08 | 0.14 | 0.09 | 0.11 | 0.08 | 0.07 | 0.07 | 0.09 | 0.04 | 0.06 | 0.12 | 0.12 |
| 17 | 0.08 | 0.10 | 0.09 | 0.11 | 0.09 | 0.13 | 0.09 | 0.13 | 0.08 | 0.08 | 0.08 | 0.11 | 0.04 | 0.09 | 0.12 | 0.13 |
| 18 | 0.09 | 0.09 | 0.15 | 0.29 | 0.07 | 0.13 | 0.62 | 0.28 | 0.08 | 0.07 | 0.13 | 0.12 | 0.04 | 0.08 | 0.19 | 0.18 |
| 19 | 0.08 | 0.09 | 0.10 | 0.10 | 0.09 | 0.16 | 0.12 | 0.13 | 0.08 | 0.07 | 0.07 | 0.14 | 0.04 | 0.08 | 0.15 | 0.14 |
| 20 | 0.07 | 0.06 | 0.06 | 0.07 | 0.06 | 0.08 | 0.08 | 0.11 | 0.08 | 0.07 | 0.07 | 0.09 | 0.04 | 0.06 | 0.09 | 0.10 |
| 21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 22 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.09 | 0.11 | 0.08 | 0.07 | 0.08 | 0.10 | 0.04 | 0.07 | 0.11 | 0.11 |
| 23 | 0.09 | 0.09 | 0.11 | 0.11 | 0.08 | 0.16 | 0.09 | 0.12 | 0.08 | 0.07 | 0.07 | 0.10 | 0.05 | 0.07 | 0.14 | 0.14 |
| 24 | 0.07 | 0.09 | 0.12 | 0.12 | 0.08 | 0.12 | 0.08 | 0.11 | 0.08 | 0.07 | 0.07 | 0.10 | 0.05 | 0.10 | 0.13 | 0.15 |
| 25 | 0.07 | 0.09 | 0.08 | 0.08 | 0.06 | 0.11 | 0.07 | 0.12 | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.11 | 0.12 |
| 26 | 0.07 | 0.09 | 0.07 | 0.08 | 0.08 | 0.10 | 0.07 | 0.10 | 0.07 | 0.07 | 0.06 | 0.05 | 0.07 | 0.08 | 0.09 | 0.11 |
| 27 | 0.07 | 0.08 | 0.07 | 0.08 | 0.06 | 0.11 | 0.07 | 0.08 | 0.06 | 0.06 | 0.06 | 0.06 | 0.08 | 0.06 | 0.09 | 0.10 |
| 28 | 0.07 | 0.08 | 0.08 | 0.08 | 0.07 | 0.50 | 0.07 | 0.10 | 0.07 | 0.06 | 0.06 | 0.06 | 0.07 | 0.06 | 0.09 | 0.10 |
| 29 | 0.42 | 0.36 | 0.45 | 0.53 | 0.22 | 0.95 | 0.29 | 0.14 | 0.21 | 0.11 | 0.09 | 0.10 | 0.09 | 0.25 | 0.59 | 0.62 |
| 30 | 0.07 | 0.07 | 0.06 | 0.07 | 0.06 | 0.09 | 0.07 | 0.09 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.12 |
| 31 | 0.05 | 0.09 | 0.09 | 0.08 | 0.06 | 0.09 | 0.07 | 0.08 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.09 | 0.09 |
| 32 | 0.06 | 0.08 | 0.06 | 0.25 | 0.06 | 0.09 | 0.06 | 0.07 | 0.06 | 0.05 | 0.06 | 0.05 | 0.07 | 0.06 | 0.09 | 0.09 |
| 33 | 0.07 | 0.08 | 0.06 | 0.07 | 0.06 | 0.08 | 0.06 | 0.07 | 0.06 | 0.05 | 0.06 | 0.05 | 0.07 | 0.06 | 0.08 | 0.09 |
| 34 | 0.07 | 0.07 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.06 | 0.09 | 0.06 | 0.15 | 0.06 | 0.06 | 0.08 | 0.08 |
| 35 | 0.18 | 0.17 | 0.27 | 1.40 | 0.25 | 0.64 | 2.10 | 0.64 | 0.10 | 0.10 | 1.22 | 1.11 | 0.05 | 0.47 | 0.95 | 0.86 |
| 36 | 0.07 | 0.07 | 0.06 | 0.07 | 0.06 | 0.11 | 0.07 | 0.08 | 0.09 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 |
| 37 | 0.10 | 0.11 | 0.11 | 0.12 | 0.09 | 0.14 | 0.12 | 0.14 | 0.09 | 0.08 | 0.08 | 0.20 | 0.10 | 0.08 | 0.14 | 0.14 |
| 38 | 0.07 | 0.08 | 0.08 | 0.09 | 0.08 | 0.11 | 0.09 | 0.11 | 0.08 | 0.07 | 0.07 | 0.07 | 0.09 | 0.08 | 0.19 | 0.11 |
| 39 | 0.08 | 0.09 | 0.07 | 0.09 | 0.07 | 0.37 | 0.09 | 0.10 | 0.08 | 0.09 | 0.09 | 0.08 | 0.09 | 0.09 | 0.11 | 0.13 |
| 40 | 0.09 | 0.16 | 0.24 | 0.12 | 0.11 | 0.16 | 0.09 | 0.12 | 0.09 | 0.09 | 0.08 | 0.08 | 0.10 | 0.09 | 0.15 | 0.16 |
| 41 | 0.08 | 0.12 | 0.10 | 0.11 | 0.10 | 0.20 | 0.09 | 0.15 | 0.09 | 0.07 | 0.09 | 0.08 | 0.11 | 0.09 | 0.15 | 0.16 |
| 42 | 0.08 | 0.11 | 0.09 | 0.10 | 0.17 | 0.23 | 0.11 | 0.19 | 0.27 | 0.12 | 0.10 | 0.09 | 0.16 | 0.42 | 0.35 | 1.24 |
| 43 | 0.09 | 0.21 | 0.11 | 0.11 | 0.10 | 0.41 | 0.10 | 0.14 | 0.08 | 0.08 | 0.08 | 0.08 | 0.12 | 0.11 | 0.20 | 0.25 |
| 44 | 0.09 | 0.11 | 0.11 | 0.12 | 0.98 | 0.15 | 0.10 | 0.14 | 0.09 | 0.09 | 0.08 | 0.08 | 0.12 | 0.13 | 0.17 | 1.25 |
| 45 | 0.08 | 0.06 | 0.06 | 0.12 | 0.10 | 0.17 | 0.10 | 0.14 | 0.09 | 0.08 | 0.06 | 0.09 | 0.11 | 0.09 | 0.16 | 0.17 |
| 46 | 0.08 | 0.08 | 0.07 | 0.09 | 0.08 | 0.22 | 0.10 | 0.12 | 0.08 | 0.07 | 0.07 | 0.07 | 0.09 | 0.08 | 0.19 | 0.26 |
| 47 | 0.07 | 0.09 | 0.08 | 0.09 | 0.09 | 0.13 | 0.09 | 0.12 | 0.07 | 0.07 | 0.07 | 0.07 | 0.10 | 0.09 | 0.15 | 0.19 |
| 48 | 0.08 | 0.11 | 0.10 | 0.12 | 0.10 | 0.16 | 0.11 | 0.13 | 0.08 | 0.09 | 0.08 | 0.08 | 0.12 | 0.09 | 0.15 | 0.15 |
| 49 | 0.09 | 0.11 | 0.10 | 0.11 | 0.10 | 0.15 | 0.15 | 0.15 | 0.08 | 0.08 | 0.07 | 0.08 | 0.10 | 0.11 | 0.26 | 0.25 |
| 50 | 0.07 | 0.09 | 0.08 | 0.09 | 0.08 | 0.86 | 0.29 | 0.18 | 0.08 | 0.07 | 0.07 | 0.07 | 0.10 | 0.20 | 0.63 | 0.46 |
| 51 | 0.06 | 0.09 | 0.08 | 0.10 | 0.12 | 0.24 | 0.13 | 0.13 | 0.07 | 0.07 | 0.08 | 0.08 | 0.11 | 0.09 | 0.24 | 0.78 |
| 52 | 0.10 | 0.13 | 0.11 | 0.11 | 0.10 | 0.20 | 0.11 | 0.13 | 0.10 | 0.09 | 0.08 | 0.08 | 0.14 | 0.11 | 0.21 | 0.38 |
| 53 | 0.12 | 0.12 | 0.09 | 0.10 | 0.08 | 0.16 | 0.09 | 0.11 | 0.09 | 0.10 | 0.08 | 0.07 | 0.09 | 0.10 | 0.16 | 0.15 |
| 54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 55 | 0.10 | 0.10 | 0.07 | 0.08 | 0.07 | 0.14 | 0.09 | 0.08 | 0.35 | 0.08 | 0.07 | 0.07 | 0.08 | 0.09 | 0.14 | 0.12 |
| 56 | 0.10 | 0.16 | 0.11 | 0.11 | 0.09 | 0.18 | 0.09 | 0.11 | 0.10 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.18 | 0.15 |
| 57 | 0.14 | 0.12 | 0.10 | 0.12 | 0.09 | 0.17 | 0.11 | 0.12 | 0.11 | 0.08 | 0.09 | 0.09 | 0.10 | 0.12 | 0.19 | 0.43 |
| 58 | 0.07 | 0.06 | 0.06 | 0.07 | 0.06 | 0.07 | 0.07 | 0.08 | 0.07 | 0.06 | 0.08 | 0.08 | 0.04 | 0.06 | 0.08 | 0.09 |
| 59 | 0.06 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.08 | 0.06 | 0.05 | 0.05 | 0.06 | 0.04 | 0.05 | 0.07 | 0.08 |
| 60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 61 | 0.07 | 0.06 | 0.06 | 0.08 | 0.06 | 0.10 | 0.07 | 0.10 | 0.08 | 0.05 | 0.06 | 0.08 | 0.04 | 0.07 | 0.12 | 0.12 |
| 62 | 0.07 | 0.07 | 0.06 | 0.09 | 0.07 | 0.08 | 0.07 | 0.09 | 0.08 | 0.05 | 0.07 | 0.11 | 0.05 | 0.07 | 0.11 | 0.14 |
| 63 | 0.11 | 0.16 | 0.12 | 0.13 | 0.11 | 0.16 | 0.11 | 0.05 | 0.08 | 0.08 | 0.08 | 0.08 | 0.11 | 0.09 | 0.15 | 0.15 |
| 64 | 0.09 | 0.08 | 0.08 | 0.09 | 0.07 | 0.10 | 0.08 | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | 0.08 | 0.11 | 0.12 |
| 65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 66 | 0.10 | 0.12 | 0.10 | 0.10 | 0.10 | 0.14 | 0.12 | 0.16 | 0.10 | 0.09 | 0.09 | 0.09 | 0.11 | 0.10 | 0.13 | 0.15 |
| 67 | 0.10 | 0.11 | 0.09 | 0.12 | 0.10 | 0.15 | 0.12 | 0.15 | 0.10 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.21 | 0.24 |
| 68 | 0.11 | 0.14 | 0.16 | 0.16 | 0.13 | 0.23 | 0.13 | 0.19 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.12 | 0.20 | 0.21 |
| 69 | 0.10 | 0.15 | 0.16 | 0.14 | 0.12 | 0.51 | 0.11 | 0.13 | 0.09 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.15 | 0.21 |
| 70 | 0.09 | 0.11 | 0.11 | 0.11 | 0.09 | 0.19 | 0.12 | 0.12 | 0.08 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.18 | 0.20 |
| 71 | 0.10 | 0.13 | 0.14 | 0.14 | 0.11 | 0.20 | 0.11 | 0.17 | 0.10 | 0.08 | 0.10 | 0.09 | 0.13 | 0.14 | 0.21 | 0.20 |
| 72 | 0.10 | 0.15 | 0.12 | 0.13 | 0.10 | 0.19 | 0.12 | 0.16 | 0.08 | 0.08 | 0.09 | 0.09 | 0.11 | 0.11 | 0.18 | 0.19 |
| 73 | 0.08 | 0.09 | 0.09 | 0.10 | 0.09 | 0.12 | 0.10 | 0.13 | 0.09 | 0.08 | 0.07 | 0.08 | 0.11 | 0.09 | 0.13 | 0.14 |
| 74 | 0.08 | 0.09 | 0.07 | 0.08 | 0.08 | 0.10 | 0.09 | 0.11 | 0.09 | 0.08 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.11 |
| 75 | 0.11 | 0.12 | 0.12 | 0.11 | 0.10 | 0.17 | 0.44 | 0.15 | 0.10 | 0.10 | 0.10 | 0.09 | 0.11 | 0.10 | 0.15 | 0.16 |
| 76 | 0.10 | 0.13 | 0.15 | 0.14 | 0.11 | 0.28 | 0.13 | 0.14 | 0.11 | 0.09 | 0.08 | 0.09 | 0.12 | 0.26 | 0.01 | 0.22 |
| 77 | 0.14 | 0.14 | 0.15 | 0.12 | 0.09 | 0.18 | 0.12 | 0.13 | 0.18 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.11 | 0.14 |
表3.在EIA中分析对与TT病毒完整开放读码框2(ORF2)对应的重叠合成肽的人抗体反应性。给出数值为405nm处的光密度。OD值大于0.500判定为阳性，并用粗体标出。
| TTVORF2肽 | 通过PCR确定为TTV DNA阴性的样品 | 通过PCR确定为TTV DNA阳性的样品 | ||||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 11 | 9 | 18 | 36 | 48 | 98 | 110 | 155 | 157 | |
| 1 | 0.09 | 0.10 | 0.13 | 0.11 | 0.10 | 0.16 | 0.09 | 0.12 | 0.08 | 0.08 | 0.09 | 0.08 | 0.08 | 0.08 | 0.14 | 0.14 |
| 2 | 0.10 | 0.11 | 0.11 | 0.10 | 0.08 | 0.12 | 0.09 | 0.14 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 | 0.14 | 0.13 |
| 3 | 0.08 | 0.10 | 0.11 | 0.10 | 0.08 | 0.29 | 0.28 | 0.14 | 0.10 | 0.08 | 0.13 | 0.08 | 0.11 | 0.10 | 0.14 | 0.04 |
| 4 | 0.09 | 0.09 | 0.08 | 0.08 | 0.07 | 0.09 | 0.07 | 0.09 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.10 | 0.10 |
| 5 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.10 | 0.08 | 0.10 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.13 |
| 6 | 0.07 | 0.10 | 0.08 | 0.10 | 0.07 | 0.10 | 0.07 | 0.10 | 0.08 | 0.28 | 0.09 | 0.08 | 0.10 | 0.09 | 0.09 | 0.11 |
| 7 | 0.11 | 0.10 | 0.11 | 0.14 | 0.91 | 0.13 | 0.10 | 0.11 | 0.08 | 0.09 | 0.10 | 0.11 | 0.10 | 0.09 | 0.10 | 0.13 |
| 8 | 0.09 | 0.10 | 0.11 | 0.13 | 0.10 | 0.12 | 0.10 | 0.14 | 0.09 | 0.08 | 0.10 | 0.11 | 0.10 | 0.10 | 0.11 | 0.12 |
| 9 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.09 | 0.11 | 0.09 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.13 | 0.14 |
| 10 | 0.09 | 0.11 | 0.10 | 0.09 | 0.08 | 0.11 | 0.08 | 0.10 | 0.09 | 0.09 | 0.07 | 0.08 | 0.08 | 0.08 | 0.11 | 0.13 |
| 11 | 0.10 | 0.10 | 0.11 | 0.08 | 0.09 | 0.09 | 0.09 | 0.11 | 0.10 | 0.12 | 0.09 | 0.07 | 0.09 | 0.09 | 0.14 | 0.14 |
| 12 | 0.12 | 0.09 | 0.09 | 0.08 | 0.09 | 0.09 | 0.08 | 0.07 | 0.13 | 0.09 | 0.08 | 0.10 | 0.14 | 0.12 | 0.16 | 0.14 |
| 13 | 0.07 | 0.09 | 0.09 | 0.08 | 0.08 | 0.10 | 0.09 | 0.11 | 0.07 | 0.08 | 0.07 | 0.08 | 0.09 | 0.08 | 0.12 | 0.12 |
| 14 | 0.08 | 0.07 | 0.08 | 0.07 | 0.07 | 0.08 | 0.08 | 0.10 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.10 | 0.10 |
| 15 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.09 | 0.07 | 0.10 | 0.08 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.10 | 0.12 |
| 16 | 0.08 | 0.09 | 0.09 | 0.07 | 0.07 | 0.09 | 0.08 | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | 0.08 | 0.12 | 0.11 |
| 17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 19 | 0.09 | 0.12 | 0.17 | 0.12 | 0.08 | 0.51 | 0.57 | 0.15 | 0.08 | 0.07 | 0.33 | 0.07 | 0.08 | 0.08 | 0.14 | 0.14 |
| 20 | 0.09 | 0.10 | 0.09 | 0.08 | 0.07 | 0.10 | 0.07 | 0.09 | 0.10 | 0.10 | 0.08 | 0.08 | 0.08 | 0.10 | 0.14 | 0.16 |
表4.与人血清样品反应的TTV肽序列.ORF1肽编号 肽序列10 VLICGENTVSRNYATHS SEQ ID NO：318 KINTMPPFLDTELTAPS SEQ ID NO：429 PDEKSQREILLNKIASY SEQ ID NO：535 TATTTTYAYPGTNRPPV SEQ ID NO：142 GLYSSIWLSPGRSYFET SEQ ID NO：644 YTDIKYNPFTDRGEGNM SEQ ID NO：750 DQNIHMNARLLIRSPFT SEQ ID NO：851 LIRSPFTDPQLLVHTDP SEQ ID NO：969 QKESLLFPPVKLLRRVP SEQ ID NO：10ORF2肽编号 肽序列19 EDGGAGGDADHGGAAGGP SEQ ID NO：11
表5.分析系列稀释的三份人血清样品与TTV肽TATTTTYAYPGTNRPPV(SEQ ID NO：1)的反应性。给出值为405nm处OD和标准差(SD)。
| 血清样品稀释度 | 人血清样品 | |||||
| P4 | SD | P6 | SD | P7 | SD | |
| 1∶100 | 1.285 | 0.072 | 0.687 | 0.082 | 1.782 | 0.054 |
| 1∶200 | 0.758 | 0.056 | 0.375 | 0.003 | 1.23 | 0.02 |
| 1∶400 | 0.411 | 0.021 | 0.19 | 0.007 | 0.79 | 0.018 |
| 1∶800 | 0.234 | 0.008 | 0.104 | 0.003 | 0.45 | 0.002 |
| 1∶1600 | 0.131 | 0.005 | 0.067 | 0.001 | 0.246 | 0.013 |
| 1∶3200 | 0.076 | 0.003 | 0.049 | 0.131 | 0.006 | |
| 1∶6400 | 0.058 | 0.001 | 0.043 | 0.087 | ||
| 1∶12800 | 0.046 | 0.041 | 0.061 | |||
表6.分析三份人血清样品对TTV肽TATTTTYAYPGTNRPPV(SEQ ID NO：1)的缺失和丙氨酸替换类似物的反应性。给出值为405nm处OD。阳性反应(即大于50％初始肽反应性)以粗体标出。
| 缺失或替代类似物 | 人血清样品P4 P7 P36 | ||
| TATTTTYAYPGTNRPPV | 0.839 | 1.845 | 0.825 |
| TATTTTYAYPGTNRPP | 0.096 | 0.144 | 0.086 |
| TATTTTYAYPGTNRP | 0.100 | 0.099 | 0.078 |
| TATTTTYAYPGTNR | 0.092 | 0.103 | 0.078 |
| TATTTTYAYPGTN | 0.186 | 0.888 | 0.083 |
| TATTTTYAYPGT | 0.095 | 0.087 | 0.072 |
| TATTTTYAYPG | 0.095 | 0.085 | 0.074 |
| TATTTTYAYP | 0.095 | 0.096 | 0.082 |
| TATTTTYAY | 0.098 | 0.089 | 0.083 |
| TATTTTYA | 0.115 | 0.089 | 0.090 |
| TATTTTY | 0.142 | 0.105 | 0.076 |
| TATTTT | 0.108 | 0.093 | 0.082 |
| TATTT | 0.101 | 0.091 | 0.078 |
| TATT | 0.099 | 0.105 | 0.076 |
| ATTTTYAYPGTNRPPV | 1.042 | 1.960 | 0.923 |
| TTTTYAYPGTNRPPV | 0.805 | 1.587 | 0.776 |
| TTTYAYPGTNRPPV | 0.697 | 1.488 | 0.810 |
| TTYAYPGTNRPPV | 0.748 | 1.659 | 0.722 |
| TYAYPGTNRPPV | 0.707 | 1.508 | 0.712 |
| YAYPGTNRPPV | 0.647 | 1.546 | 0.677 |
| AYPGTNRPPV | 0.662 | 1.488 | 0.669 |
| YPGTNRPPV | 0.300 | 1.091 | 0.406 |
| PGTNRPPV | 0.166 | 0.430 | 0.123 |
| GTNRPPV | 0.300 | 0.887 | 0.210 |
| TNRPPV | 0.110 | 0.146 | 0.056 |
| NRPPV | 0.135 | 0.242 | 0.076 |
| AATTTTYAYPGTNRPPV | 1.045 | 1.852 | 0.915 |
| TGTTTTYAYPGTNRPPV | 0.855 | 1.829 | 0.806 |
| TAATTTYAYPGTNRPPV | 0.897 | 1.675 | 0.764 |
| TATATTYAYPGTNRPPV | 0.971 | 1.722 | 0.824 |
| TATTATYAYPGTNRPPV | 1.076 | 1.867 | 0.955 |
| TATTTAYAYPGTNRPPV | 1.011 | 1.833 | 1.027 |
| TATTTTAAYPGTNRPPV | 0.898 | 1.619 | 0.901 |
| TATTTTYGYPGTNRPPV | 0.836 | 1.769 | 0.850 |
| TATTTTYAAPGTNRPPV | 0.899 | 1.697 | 0.903 |
| TATTTTYAYAGTNRPPV | 0.886 | 1.738 | 0.903 |
| TATTTTYAYPATNRPPV | 0.895 | 1.503 | 0.734 |
| TATTTTYAYPGANRPPV | 0.891 | 1.594 | 0.714 |
| TATTTTYAYPGTARPPV | 1.226 | 1.723 | 0.696 |
| TATTTTYAYPGTNAPPV | 0.761 | 1.558 | 0.708 |
| TATTTTYAYPGTNRAPV | 0.720 | 1.551 | 0.812 |
| TATTTTYAYPGTNRPAV | 0.090 | 0.092 | 0.100 |
| TATTTTYAYPGTNRPPA | 0.108 | 0.105 | 0.095 |
参考文献
1.Nishizawa T，Okamoto H，Konishi K，Yoshizawa H，MiyakawaY，Mayumi M，与未知病因输血后肝炎中转氨酶水平升高相关的一种新型DNA病毒(A novel DNA virus(TTV)associated with elevated transaminaselevels in posttransfusion hepatitis of unknown etiology)，生物化学和生物物理研究通讯(Biochem Biophys Res Commun)1997；241：92-7
2.Okamoto H，Akahane Y，Ukita M，Fukuda M，Tsuda F，MiyakawaY，Mayumi M.粪便排出一种与输血后非甲-庚型肝炎相关的非包膜DNA病毒(TTV)(Fecal excreton of a nonenveloped DNA virus(TTV)associatedwith posttransfusion non-A-G hepatitis)，医学病毒学杂志(J MedVirol)1998；56：128-32
3.Cossart Y.TTV，一种常见病毒，但是致病？(TTV a commonvirus，but pathogenic？)，[评论]。Lancet 1998；352：164
4.Okamoto H，Kato N，Iizuka H，Tsuda F，Miyakawa Y，Mayumi M.血浆或外周血单核细胞中与输血后非甲-庚型肝炎相关的非包膜DNA病毒(TT病毒)的独特基因型(Distinct genotypes of a nonenveloped DNA virusassociated with posttransfusion non-A-G hepatitis(TT virus)inplasma and peripheral blood mononuclear cells)[In process Citation].医学病毒学杂志1999；57：252-8
5.Naoumov NV，Petrova EP，Thomas MG，Williams R.肝病患者中存在一种新描述的人类DNA病毒(TTV)(Presence of a newly describedhuman DNA virus (TTV) in patients with liver disease[seecomments])，Lancet 1998；352：195-7
6.Viazov S，Ross RS，Varenholz C，Lange R，Holtmann M，NielC，Roggendorf M.TTV感染和严重肝病的相关性缺乏证据(Lack of evidencefor an association between TTV infection and severe liver disease[Inprocess Citation])。临床病毒学杂志(J Clin Virol)1998；11：183-7
7.Sllberg M，Ruden U，Magnius LO，Norrby E，Wahren B.使用9-芴基甲氧基羰基(Fmoc)保护的氨基酸的快速“茶包”肽合成法应用于病毒蛋白的抗原性作图(Rapid‘tea-bag’peptide synthesis using 9-fluorenylmethoxycarbonyl(Fmoc)protected amino acids applied forantigenic maping of viral proteins)。免疫学通讯(ImmunologyLetters)1991；30：59-68
8.Zhang ZX，Chen M，Hultgren C，Birkett A，Milich DR，Sallberg M.病毒基因型和宿主主要组织相容性复合物显著影响针对丙型肝炎病毒NS4a的免疫应答(Immune responses to the hepatitis C virus NS4a areprofoundly influenced by the combination of the viral genotype andthe host major histocompatibility complex)。普通病毒学杂志(J.Gen.Virol.)1997；78：2735-2746序列表<110>Tripep AB<120>来自TT病毒序列的肽和结合TT病毒的单特异性抗体<130>192975901<140><141><160>11<170>PatentIn Ver.2.1<210>1<211>17<212>PRT<213>TT病毒<400>1Thr Ala Thr Thr Thr Thr Tyr Ala Tyr Pro Gly Thr Asn Arg Pro pro1 5 10 15Val<210>2<211>11<212>PRT<213>TT病毒<400>2Tyr Ala Tyr Pro Gly Thr Asn Arg Pro Pro Val1 5 10<210>3<211>17<212>PRT<213>TT病毒<400>3Val Leu Ile Cys Gly Glu Asn Thr Val Ser Arg Asn Tyr Ala Thr His1 5 10 15Ser<210>4<211>17<212>PRT<213>TT病毒<400>4Lys Ile Asn Thr Met Pro Pro Phe Leu Asp Thr Glu Leu Thr Ala Pro1 5 10 15Ser<210>5<211>17<212>PRT<213>TT病毒<400>5Pro Asp Glu Lys Ser Gln Arg Glu Ile Leu Leu Asn Lys Ile Ala Ser1 5 10 15Tyr<210>6<211>17<212>PRT<213>TT病毒<400>6Gly Leu Tyr Ser Ser Ile Trp Leu Ser Pro Gly Arg Ser Tyr Phe Glu1 5 10 15Thr<210>7<211>17<212>PRT<213>TT病毒<400>7Tyr Thr Asp Ile Lys Tyr Asn Pro Phe Thr Asp Arg Gly Glu Gly Asn1 5 10 15Met<210>8<211>17<212>PRT<213>TT病毒<400>8Asp Gln Asn Ile His Met Asn Ala Arg Leu Leu Ile Arg Ser Pro Phe1 5 10 15Thr<210>9<211>17<212>PRT<213>TT病毒<400>9Leu Ile Arg Ser Pro Phe Thr Asp Pro Gln Leu Leu Val His Thr Asp1 5 10 15Pro<210>10<211>17<212>PRT<213>TT病毒<400>10Gln Lys Glu Ser Leu Leu Phe Pro Pro Val Lys Leu Leu Arg Arg Val1 5 10 15Pro<210>11<211>18<212>PRT<213>TT病毒<400>11Glu Asp Gly Gly Ala Gly Gly Asp Ala Asp His Gly Gly Ala Ala Gly1 5 10 15Gly Pro
Claims (12)
1.具有氨基酸序列SEQ ID NO：1Thr Ala Thr Thr Thr Thr Tyr Ala Tyr Pro Gly Thr Asn Arg Pro ProVal的肽，其中N-端氨基酸Thr Ala Thr Thr Thr Thr中的一到六个可以去除。
2.根据权利要求1的肽，其具有氨基酸序列SEQ ID NO：2Tyr Ala Tyr Pro Gly Thr Asn Arg Pro Pro Val。
3.肽混合物，其包含根据权利要求1的肽和至少一个以下肽：SEQ ID NO：3Val Leu Ile Cys Gly Glu Asn Thr Val Ser Arg Asn Tyr Ala Thr HisSer，SEQ ID NO：4Lys Ile Asn Thr Met Pro Pro Phe Leu Asp Thr Glu Leu Thr Ala ProSer，SEQ ID NO：5Pro Asp Glu Lys Ser Gln Arg Glu Ile Leu Leu Asn Lys Ile Ala SerTyr，SEQ ID NO：6Gly Leu Tyr Ser Ser Ile Trp Leu Ser Pro Gly Arg Ser Tyr Phe GluThr，SEQ ID NO：7Tyr Thr Asp Ile Lys Tyr Asn Pro Phe Thr Asp Arg Gly Glu Gly AsnMet，SEQ ID NO：8Asp Gln Asn Ile His Met Asn Ala Arg Leu Leu Ile Arg Ser Pro PheThr，SEQ ID NO：9Leu Ile Arg Ser Pro Phe Thr Asp Pro Gln Leu Leu Val His Thr AspPro，SEQ ID NO：10Gln Lys Glu Ser Leu Leu Phe Pro Pro Val Lys Leu Leu Arg Arg ValPro，和SEQ ID NO：11Glu Asp Gly Gly Ala Gly Gly Asp Ala Asp His Gly Gly Ala Ala GlyGly Pro。
4.根据权利要求1或2的肽，或根据权利要求3的肽混合物，其中至少一个肽被偶联到载体和/或标记上。
5.根据权利要求1或2的肽，或根据权利要求3的肽混合物，其中至少一个肽被固定到固相上。
6.根据前述权利要求之任何一项的肽或肽混合物，用于药物。
7.结合TT病毒的单特异性抗体。
8.根据权利要求7的单特异性抗体，其结合选自氨基酸序列SEQ IDNO：1-11的氨基酸序列。
9.根据权利要求7或8的用于药物的单特异性抗体。
10.包含根据权利要求1-5之任一项的肽或肽混合物作为诊断抗原的诊断试剂盒。
11.包含一个或多个根据权利要求7或8的单特异性抗体作为诊断抗体的诊断试剂盒。
12.根据权利要求1-4之任一项的肽或肽混合物在免疫非人哺乳动物产生抗TT病毒的单特异性抗体中的用途。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE99016016 | 1999-05-04 | ||
| SE9901601A SE9901601D0 (sv) | 1999-05-04 | 1999-05-04 | Peptides from the TT virus sequence and monospecific antibodies binding to the TT virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1352649A true CN1352649A (zh) | 2002-06-05 |
Family
ID=20415453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00807153A Pending CN1352649A (zh) | 1999-05-04 | 2000-05-03 | 来自tt病毒序列的肽和结合tt病毒的单特异性抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030022158A1 (zh) |
| EP (1) | EP1177210A1 (zh) |
| JP (1) | JP2003502285A (zh) |
| KR (1) | KR20020008172A (zh) |
| CN (1) | CN1352649A (zh) |
| AU (1) | AU4560800A (zh) |
| CA (1) | CA2370495A1 (zh) |
| CZ (1) | CZ20013638A3 (zh) |
| HU (1) | HUP0200869A2 (zh) |
| IL (1) | IL145848A0 (zh) |
| IS (1) | IS6143A (zh) |
| NO (1) | NO20015376L (zh) |
| PL (1) | PL352064A1 (zh) |
| RU (1) | RU2001127439A (zh) |
| SE (1) | SE9901601D0 (zh) |
| WO (1) | WO2000066621A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933366B2 (en) | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
| US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| WO2004067549A2 (de) * | 2003-01-31 | 2004-08-12 | Max-Delbrück-Centrum für Molekulare Medizin | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung |
| US7335359B2 (en) | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
| EP1594898A2 (en) | 2003-02-06 | 2005-11-16 | Tripep AB | Glycosylated specificity exchangers |
| WO2008127279A2 (en) * | 2006-10-05 | 2008-10-23 | Cerebus Biologicals, Inc. | Methods for treating, preventing and diagnosing porcine ttv infection |
| AU2009303845B2 (en) | 2008-10-16 | 2013-09-12 | Zoetis Llc | Torque teno virus (TTV) isolates and compositions |
| US8846388B2 (en) | 2009-10-16 | 2014-09-30 | Zoetis Llc | Infectious clones of torque teno virus |
| MX2012004448A (es) * | 2009-10-16 | 2012-05-08 | Pfizer | Clones infecciosos de torque teno virus. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010022220A (ko) * | 1997-07-25 | 2001-03-15 | 다무라 료지 | 비-ｂ형 비-ｃ형 비-ｇ형 간염 바이러스 유전자,폴리뉴클레오티드, 폴리펩티드, 바이러스 입자, 바이러스입자의 분리 방법, 및 바이러스의 검출 방법 |
| AU4259299A (en) * | 1998-05-13 | 1999-11-29 | Innogenetics N.V. | New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections |
| JP2000135087A (ja) * | 1998-10-29 | 2000-05-16 | Srl Inc | 抗ｔｔウイルス抗体測定用ペプチド及びそれを用いたｔｔウイルスの血清型分類方法 |
-
1999
- 1999-05-04 SE SE9901601A patent/SE9901601D0/xx unknown
-
2000
- 2000-05-03 IL IL14584800A patent/IL145848A0/xx unknown
- 2000-05-03 RU RU2001127439/13A patent/RU2001127439A/ru unknown
- 2000-05-03 JP JP2000615650A patent/JP2003502285A/ja active Pending
- 2000-05-03 AU AU45608/00A patent/AU4560800A/en not_active Abandoned
- 2000-05-03 CZ CZ20013638A patent/CZ20013638A3/cs unknown
- 2000-05-03 CA CA002370495A patent/CA2370495A1/en not_active Abandoned
- 2000-05-03 KR KR1020017013998A patent/KR20020008172A/ko not_active Application Discontinuation
- 2000-05-03 PL PL00352064A patent/PL352064A1/xx unknown
- 2000-05-03 CN CN00807153A patent/CN1352649A/zh active Pending
- 2000-05-03 WO PCT/EP2000/003958 patent/WO2000066621A1/en not_active Application Discontinuation
- 2000-05-03 EP EP00927128A patent/EP1177210A1/en not_active Withdrawn
- 2000-05-03 HU HU0200869A patent/HUP0200869A2/hu unknown
-
2001
- 2001-11-01 IS IS6143A patent/IS6143A/is unknown
- 2001-11-02 NO NO20015376A patent/NO20015376L/no not_active Application Discontinuation
- 2001-11-05 US US09/992,896 patent/US20030022158A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IS6143A (is) | 2001-11-01 |
| PL352064A1 (en) | 2003-07-28 |
| KR20020008172A (ko) | 2002-01-29 |
| NO20015376D0 (no) | 2001-11-02 |
| NO20015376L (no) | 2001-12-06 |
| IL145848A0 (en) | 2002-07-25 |
| HUP0200869A2 (en) | 2002-08-28 |
| US20030022158A1 (en) | 2003-01-30 |
| JP2003502285A (ja) | 2003-01-21 |
| WO2000066621A1 (en) | 2000-11-09 |
| EP1177210A1 (en) | 2002-02-06 |
| RU2001127439A (ru) | 2004-02-27 |
| SE9901601D0 (sv) | 1999-05-04 |
| CA2370495A1 (en) | 2000-11-09 |
| AU4560800A (en) | 2000-11-17 |
| CZ20013638A3 (cs) | 2002-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gigler et al. | Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins | |
| EP0804584B2 (en) | Sequences of hepatitis c virus genotype 7 and their use as prophylactic, therapeutic and diagnostic agents | |
| JP2532805B2 (ja) | Ｎａｎｂｖの診断用薬およびワクチン | |
| Kanto et al. | Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence | |
| US7611719B2 (en) | Enterovirus, vaccines, medicaments and diagnostic kits | |
| Feucht et al. | Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients | |
| Zuffi et al. | Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans | |
| Stuyver et al. | Analysis of the putative E1 envelope and NS4a epitope regions of HCV type 3 | |
| CN1352649A (zh) | 来自tt病毒序列的肽和结合tt病毒的单特异性抗体 | |
| Odeberg et al. | Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients | |
| Yashina et al. | Detection of hepatitis G virus (HGV) RNA: clinical characteristics of acute HGV infection | |
| Ferroni et al. | Identification of four epitopes in hepatitis C virus core protein | |
| US20060078932A1 (en) | Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes | |
| Kim et al. | Molecular characterization of the hepatitis G virus | |
| Lechner et al. | Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1 | |
| UA73475C2 (en) | Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis | |
| JPH0940694A (ja) | 肝炎ｇｂウイルスの合成ペプチド及びその使用 | |
| US20080089903A1 (en) | Cd4+t-lymphocyte-specific hepatitis c virus epitopes | |
| WO1999058638A2 (en) | Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections | |
| US20140128447A1 (en) | Novel non-primate hepacivirus | |
| Park et al. | GB virus C/hepatitis G virus infection among Korean patients with liver diseases and general population | |
| De Cock et al. | Serotyping and genotyping of hepatitis C virus in Belgium | |
| JP2001524821A (ja) | Ｅ型肝炎のパキスタン株組換えタンパク質および診断法およびワクチンにおけるそれらの使用 | |
| US7070790B1 (en) | Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines | |
| Zhang et al. | Dynamic changes in hepatitis C virus genotypes and sequence patterns in plasma donors exposed to reinfection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |